secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2022-05-03T23:59:59+00:00
Accession:  0001323885-22-000055
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q1 revenue $74.6M (+25.8% YoY); guides FY22 rev $318-330M
------------------------------------------------------------------

- Revenue $74.6M, up 25.8% YoY; U.S. $62.3M (+23.8%), intl $12.3M (+37.2%).
- Gross margin 74.5% vs 75.1% YoY; operating loss narrowed to $14.2M from $15.9M.
- GAAP net loss $0.33/share; adjusted loss $0.33/share; adj EBITDA loss $4.2M.
- FY 2022 rev guidance $318-330M (+16-20%); adj EPS loss $1.07-$1.12.
- CEO cites broad-based growth; EPi-Sense adoption, Cryo Nerve Block expansion, EnCompass launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388522000055/0001323885-22-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388522000055/atrc-20220503.htm
  HTML page:      https://secwatch.observer/filing/0001323885-22-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer